Elfabrio Side Effects

Generic name: pegunigalsidase alfa

Medically reviewed by Drugs.com. Last updated on Apr 26, 2024.

Note: This document provides detailed information about Elfabrio Side Effects associated with pegunigalsidase alfa. Some dosage forms listed on this page may not apply specifically to the brand name Elfabrio.

Applies to pegunigalsidase alfa: intravenous solution.

Important warnings This medicine can cause some serious health issues

Intravenous route (solution)

Warning: Hypersensitivity Reactions including Anaphylaxis. Patients treated with pegunigalsidase alfa-iwxj have experienced hypersensitivity reactions, including anaphylaxis.

Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during pegunigalsidase alfa-iwxj administration.

If a severe hypersensitivity reaction (eg, anaphylaxis) occurs, discontinue pegunigalsidase alfa-iwxj immediately and initiate appropriate medical treatment.

In patients with severe hypersensitivity reaction, a desensitization procedure to pegunigalsidase may be considered.

Serious side effects of Elfabrio

Along with its needed effects, pegunigalsidase alfa (the active ingredient contained in Elfabrio) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking pegunigalsidase alfa:

More common side effects

• back pain
• bloody or cloudy urine
• burning, numbness, tingling, or painful sensations
• chest tightness
• chills
• cough
• ear congestion
• fast heartbeat
• fever
• flushing
• headache
• loss of voice
• muscle aches
• nausea and vomiting
• nerve pain
• pain in the arms, legs, lower back, bottom, or hips
• skin itching, rash, or redness
• sneezing
• sore throat
• stuffy or runny nose
• swelling of the face, throat, or tongue
• trouble breathing
• trouble swallowing
• unsteadiness or awkwardness
• unusual tiredness or weakness
• weakness in the arms, hands, legs, or feet

Incidence unknown

• blurred vision
• chest pain or discomfort
• confusion
• dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
• nervousness
• pounding in the ears
• puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
• shakiness in the legs, arms, hands, or feet
• slow or irregular heartbeat
• sweating
• swelling of the face, feet, or lower legs
• trembling or shaking of the hands or feet
• vomiting

Other side effects of Elfabrio

Some side effects of pegunigalsidase alfa may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

• diarrhea
• pain or tenderness around the eyes and cheekbones
• stomach pain

Incidence not known

• burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
• difficulty in moving
• joint pain
• lack or loss of strength
• muscle cramps, pains, or stiffness
• sneezing
• swollen joints
• throat irritation

For healthcare professionals

Applies to pegunigalsidase alfa: intravenous solution.

General adverse events

The most common adverse reactions reported in 15% of patients or greater included infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis.^[Ref]

Gastrointestinal

• Very common (10% or more): Diarrhea (19%), nausea (17%), abdominal pain (12%)^[Ref]

Hypersensitivity

• Very common (10% or more): Hypersensitivity reactions (up to 14%)
• Common (1% to 10%): Anaphylaxis (3%)^[Ref]

Hypersensitivity and anaphylactic reactions included headache, nausea, vomiting, throat tightness, facial and oral edema, truncal rash, macular rash, tachycardia, hypotension, rigors, urticaria, intense pruritus, moderate upper airway obstructions, macroglossia, and mild lip edema.^[Ref]

Local

• Very common (10% or more): Infusion-associated reactions (up to 32%)
• Common (1% to 10%): Infusion-site extravasation^[Ref]

Infusion-associated reactions included nausea, chills, pruritus, rash, chest pain, dizziness, vomiting, asthenia, pain, sneezing, dyspnea, nasal congestion, throat irritation, abdominal pain, erythema, diarrhea, burning sensation, neuralgia, headache, paresthesia, tremor, agitation, increased body temperature, flushing, bradycardia, myalgia, hypertension, and hypotension. These events occurred within 24 hours of infusion.^[Ref]

Musculoskeletal

• Very common (10% or more): Back pain (15%), pain in extremity (15%)^[Ref]

Nervous system

• Very common (10% or more): Headache (21%)
• Common (1% to 10%): Neuralgia, peripheral neuropathy, sciatica^[Ref]

Other

• Very common (10% or more): Fatigue (17%)^[Ref]

Respiratory

• Very common (10% or more): Nasopharyngitis (up to 21%), sinusitis (15%)
• Common (1% to 10%): Upper respiratory tract congestion^[Ref]

Renal

• Very common (10% or more): Proteinuria (12%)
• Common (1% to 10%): Hematuria
• Frequency not reported: Membranoproliferative glomerulonephritis^[Ref]

Further information

Elfabrio side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer